Screens for variants in genes associated with an increased high risk of colorectal and endometrial cancers.
A diagnosis of Lynch Syndrome is confirmed by the detection of a pathogenic germline variant in one of the MMR genes (MLH1, MSH2, MSH6 and PMS2) or the EPCAM gene.
Lynch Syndrome Gene Panel
Used for investigation of Lynch Syndrome in patients with colorectal cancer or endometrial cancer where there is a familial risk of ≥10%.
MLH1, MSH2, MSH6, PMS2, EPCAM
Massively Parallel Sequencing
4 weeks
73354 – conditions apply
$479 if not Medicare eligible
Cancer Genetics request form preferred. Standard pathology request form accepted.
Blood x 2
6mL EDTA
2 x Bloods taken at 10 minute intervals. Pre test genetic counselling required. Patient to sign consent form prior to testing.
